Your session is about to expire
← Back to Search
Pacritinib for Prostate Cancer (BLAST Trial)
BLAST Trial Summary
This trial is testing a drug called pacritinib for men with prostate cancer who have already had treatment.
BLAST Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowBLAST Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 1 & 2 trial • 40 Patients • NCT02891603BLAST Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My kidney function, measured by GFR, is above 45 ml/min.I haven't taken any 5-alpha reductase inhibitors in the last 42 days.My liver is not working well (severe issues).My scans show no clear signs of cancer spread, except possibly small lymph nodes or uncertain bone lesions.My prostate cancer was confirmed through a tissue test.I do not have a prolonged QT interval (>450 ms) or conditions like heart failure.I've had hormone therapy for prostate cancer more than 9 months ago, lasting no more than 3 years.My scans show no clear signs of cancer spread, except possibly small lymph nodes or uncertain bone lesions.I have had surgery or radiation for prostate cancer.I have been treated with pacritinib before.My blood tests show my organs are working well.I have never been treated with JAK2 inhibitors.I haven't taken strong CYP3A4 inhibitors or inducers in the last 14 days.I have had radiation before or cannot have it due to my health and cancer type.I haven't had serious bleeding issues in the last 3 months.I haven't taken any prohibited medications in the last week.I do not have an active hepatitis A, B, or C infection.I have had chemotherapy for prostate cancer less than 6 months ago, but only as part of initial treatment.I take more than 10 mg of prednisone or equivalent daily for a chronic condition.My heart condition limits my physical activity.I am 18 years old or older.I am a male and agree to use effective contraception during and for 60 days after the study.My prostate cancer was confirmed through a tissue test.My liver tests are within normal limits.My blood potassium level is at least 3.5 mmol/L.My hemoglobin level is at least 9.0 g/dL without needing transfusions or growth factors in the last 3 months.I have had surgery or radiation for prostate cancer.I am fully active or able to carry out light work.I haven't had any cancer other than certain skin, cervical, or in situ breast cancers in the last 3 years.I haven't taken any blood-thinning or certain anti-inflammatory drugs in the last 14 days.My prostate cancer has returned, and my PSA levels are rising quickly.I've had radiation before or can't have it due to my health and cancer type.I haven't taken any medications that affect heart rhythm timing in the last 14 days.My prostate cancer has returned, and my PSA levels are doubling in 9 months or less.I have never been treated with JAK2 inhibitors.You are willing to give blood and tissue samples for research purposes, but it's not required to be in the trial.I am fully active or able to carry out light work.My heart pumps well, with an ejection fraction of 50% or higher.I am 18 years old or older.I have had surgery to remove both testicles.My blood pressure is not controlled by medication.I do not have stomach or metabolic issues affecting medication absorption.I have an active or uncontrolled bowel disorder like Crohn's disease.I have been treated with specific hormone therapies for cancer.
- Group 1: Pacritinib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What other analyses have been conducted in relation to Pacritinib?
"Currently, 6 trials are running for Pacritinib. Out of those investigations, 1 is in its third and final phase. While the majority of these clinical studies take place around Tampa, Florida; 172 other medical sites have been enlisted to host research into this treatment option."
Does this research mark a precedent in its field?
"Presently, 48 cities across 22 nations are hosting 6 active clinical trials for Pacritinib. The initial trial of this drug was administered by CTI BioPharma in 2017 with 43 patients and went through the phase 1 & 2 approval process. Subsequently, 11 more studies have been completed since then."
What is the current patient quota for this research endeavor?
"Affirmative. The clinicaltrial.gov website has verified that this trial is actively enrolling participants, which began recruitment on June 1st 2021 and was last updated July 18th 2022. 46 volunteers are needed for the single study location."
What adverse effects might individuals experience from taking Pacritinib?
"Pacritinib's safety was assigned a rating of 2 due to its Phase 2 trial status, that is, there exists evidence supporting pacritinib's security yet no clinical data for efficacy."
Is this exploration actively seeking out participants?
"According to the clinicaltrials.gov website, this research endeavour is presently recruiting volunteers; it was first advertised on June 1st 2021 and has been recently modified as of July 18th 2022."
Share this study with friends
Copy Link
Messenger